Prime Medicine to Present at Upcoming Investor Conferences
19 September 2023 - 2:00PM
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company
committed to delivering a new class of differentiated one-time
curative genetic therapies, today announced that Keith
Gottesdiener, M.D., President and Chief Executive Officer of Prime
Medicine, will present at three upcoming investor conferences:
- BMO Biopharma Virtual Spotlight Series: Latest Advances
in Genome / Epigenome Editing: Fireside chat on Tuesday,
September 26, 2023, at 10:30 a.m. ET.
- Jefferies Cell & Genetic
Medicine Summit (New York, NY): Fireside chat on
Wednesday, September 27, 2023, at 9:00 a.m. ET.
- Chardan’s
7th Annual Genetic Medicines
Conference (New York, NY):
- Fireside chat on Tuesday, October 3,
2023, at 2:30 p.m. ET.
- Panel discussion, “Next-Gen Genome
Editing,” on Tuesday, October 3, 2023, at 4:00 pm ET.
Live audio webcasts of the Jefferies and Chardan fireside chats
will be available under “Events & Presentations” in the News
& Events section of the Company’s website at
www.primemedicine.com. In addition, replays of the BMO fireside
chat and Chardan panel discussion will become available after the
presentations conclude. Replays of all webcasts will be available
on the Prime Medicine website for 30 days following the
presentation.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to
creating and delivering the next generation of gene editing
therapies to patients. The Company is leveraging its proprietary
Prime Editing platform, a versatile, precise and efficient gene
editing technology, to develop a new class of differentiated,
one-time, potentially curative genetic therapies. Designed to make
only the right edit at the right position within a gene while
minimizing unwanted DNA modifications, Prime Editors have the
potential to repair almost all types of genetic mutations and work
in many different tissues, organs and cell types.
Prime Medicine is currently progressing a diversified portfolio
of eighteen programs initially focused on genetic diseases with a
fast, direct path to treating patients or with a high unmet need
because they cannot be treated using other gene-editing approaches.
Over time, the Company intends to maximize Prime Editing’s
therapeutic potential and advance potentially curative therapeutic
options to patients for a broad spectrum of diseases. For more
information, please visit www.primemedicine.com.
© 2023 Prime Medicine, Inc. All rights reserved.
PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are
trademarks of Prime Medicine, Inc. All other trademarks referred to
herein are the property of their respective owners.
Investor Contact
Hannah DeresiewiczStern Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media Contact
Dan Budwick, 1ABdan@1ABmedia.com
Prime Medicine (NASDAQ:PRME)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Prime Medicine (NASDAQ:PRME)
Historical Stock Chart
Von Mai 2023 bis Mai 2024